• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Larimar Therapeutics Inc. (Amendment)

    2/14/24 4:46:08 PM ET
    $LRMR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LRMR alert in real time by email
    SC 13G/A 1 d781817dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Larimar Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    517125 100

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 517125 100

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA


    CUSIP No. 517125 100

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN


    CUSIP No. 517125 100

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     0

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     0%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO


    Item 1(a).

    Name of Issuer:

    Larimar Therapeutics, Inc. (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    Three Bala Plaza East. Suite 506, Bala Cynwyd, Pennsylvania, 19004

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e).

    CUSIP Number:

    517125 100

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages reported are based on 43,905,903 outstanding shares of Common Stock, as reported in the Issuer’s Form 10-Q filed on November 14, 2023.


    The Master Fund directly holds 0 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member

     

    /s/ Joseph Edelman
    JOSEPH EDELMAN

     

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title: Managing Member
    Get the next $LRMR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LRMR

    DatePrice TargetRatingAnalyst
    1/29/2025$18.00Buy
    Truist
    10/16/2024$26.00Outperform
    Oppenheimer
    10/3/2024$22.00Outperform
    Wedbush
    10/2/2024$15.00Buy
    H.C. Wainwright
    9/4/2024$16.00Outperform
    Robert W. Baird
    4/3/2024$25.00Outperform
    Leerink Partners
    11/17/2023$4.50Neutral → Buy
    Citigroup
    10/19/2022$12.00Buy
    Guggenheim
    More analyst ratings

    $LRMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hamilton Thomas Edward bought $499,998 worth of shares (57,208 units at $8.74), increasing direct ownership by 11% to 564,798 units (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/31/24 4:56:58 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flynn James E bought $37,499,993 worth of shares (4,290,617 units at $8.74) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/16/24 2:37:50 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thomas Frank E bought $22,000 worth of shares (2,000 units at $11.00) (SEC Form 4)

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      2/15/24 4:21:16 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Larimar Therapeutics with a new price target

      Truist initiated coverage of Larimar Therapeutics with a rating of Buy and set a new price target of $18.00

      1/29/25 7:39:50 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Larimar Therapeutics with a new price target

      Oppenheimer initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $26.00

      10/16/24 7:29:15 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Larimar Therapeutics with a new price target

      Wedbush initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $22.00

      10/3/24 7:34:56 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by * Director by Deputization Flynn James E

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/15/25 7:44:19 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sherman Jeffrey W

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/14/25 4:34:08 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Truitt Joseph

      4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)

      5/14/25 4:33:51 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

      Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar's planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed articles highlighting nonclinical data on the therapeutic potential, pharmacology, and mechanism of action of nomlabofusp as a novel frataxin (FXN) protein replacement therapy designed to address t

      7/8/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

      Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLAWritten FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for adults and childrenOLE data expected in September 2025 from 30-40 participants who received at least one dose of nomlabofusp; data will include participants on the 50 mg doseAdolescent PK run-in data e

      6/23/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

      BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company's nomlabofusp clinical development program for the treatment of Friedreich's Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to confe

      6/20/25 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    SEC Filings

    See more
    • Larimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

      6/23/25 5:13:27 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)

      6/23/25 7:02:41 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Larimar Therapeutics Inc.

      SCHEDULE 13G - Larimar Therapeutics, Inc. (0001374690) (Subject)

      6/17/25 4:12:15 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

      BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company's Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in regulatory and clinical strategy. "Dr. Sherman is a pharmaceutical industry veteran who brings decades of leadership experience in global regulatory and clinical strategy to our Board of Directors.

      10/3/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

      Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2 dataInitiation cleared for open-label extension (OLE) trial following FDA review of unblinded 25 mg cohort Phase 2 dataTop-line safety, pharmacokinetic, and frataxin data from the Phase 2 trial's 50 mg cohort expected in 1H 2024Initiation of OLE trial with 25 mg daily dosing expected in Q1 2024; interim data expected in Q4 2024 Cash, cash equivalents and marketable securities of $104.2 million as of June 30, 2023, provides projected cash runway into Q4 2024 BALA CYNWYD, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Lari

      8/10/23 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

      BALA CYNWYD, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ("Larimar") (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Russell "Rusty" Clayton, DO, as Chief Medical Officer ("CMO"), effective today. Dr. Clayton succeeds former CMO Nancy M. Ruiz, MD, who is retiring and will provide consulting support to the Company as needed. "We are delighted to welcome Dr. Clayton in his new role as CMO as we further expand our clinical development of CTI-1601. Rusty has been one of our closest advisors for the last 5 years, has attended every meeting between Larimar and the FDA, in

      7/17/23 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Financials

    Live finance-specific insights

    See more
    • Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

      Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLAWritten FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for adults and childrenOLE data expected in September 2025 from 30-40 participants who received at least one dose of nomlabofusp; data will include participants on the 50 mg doseAdolescent PK run-in data e

      6/23/25 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

      BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company's nomlabofusp clinical development program for the treatment of Friedreich's Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to confe

      6/20/25 4:05:00 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

      Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) studyTissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in buccal cells and 9.28 pg/μg in skin cells at Day 90Tissue FXN levels increased and were maintained over time, with mean levels increasing from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90Early trends towards improvement in clinical outcomes were observed at Day 90, supporting the potential that nomlabofusp administration may result in a clinical benefit across a broad spectrum of patient

      12/16/24 7:00:00 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LRMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 5:05:19 PM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 11:41:09 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Larimar Therapeutics Inc.

      SC 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)

      11/14/24 9:16:35 AM ET
      $LRMR
      Biotechnology: Pharmaceutical Preparations
      Health Care